Amy Swerczek, APRN
Acute Care · Omaha, NENPI 1093002255
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 111 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AstraZeneca at 30.3% of the total. Reporting peaked in 2024 at $787 and has fallen 89.0% since, to $86 in 2025.
Across 111 payments — averaging $21.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$739
- Amgen$217
- Jazz Pharmaceuticals Inc.$202
- Electromed, Inc.$173
- Boehringer Ingelheim$140
- Harmony Biosciences LLC$124
- plus $843 from 19 others
What the payments were for
- Food & beverage$2,437100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,437 in reported general payments places this provider in the 85th percentile of 103 acute care providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 184 | $150,792 |
| Breo ElliptaFluticasone/Vilanterol | 97 | $41,075 |
| Spiriva RespimatTiotropium Bromide | 22 | $16,692 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $16,376 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $13,291 |
| EliquisApixaban | 19 | $12,244 |
| Incruse ElliptaUmeclidinium Bromide | 22 | $9,592 |
| Arnuity ElliptaFluticasone Furoate | 27 | $9,086 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $6,505 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $5,703 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $3,848 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 19 | $3,766 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 33 | $3,464 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 113 | $2,416 |
| Ventolin HfaAlbuterol Sulfate | 20 | $1,089 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $39 | $226,921363 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $140 | $22,39534 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $739 | $19,79645 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 103 acute care providers in Nebraska.
Other acute care in Omaha
- Jennifer BecherOmaha$7K
- Mary LauerOmaha$7K
- Rachel RagerOmaha$6K
- Brittany KellyOmaha$4K
- Angela ClabornOmaha$3K
- Stephanie ChristensenOmaha$2K
- Angela SivertsonOmaha$2K
- Cassandra KaczmarekOmaha$2K
- Elisabeth ElganOmaha$1K
- Andrea KaufmanOmaha$759
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.